Youram Nassir

644 total citations
39 papers, 490 citations indexed

About

Youram Nassir is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Youram Nassir has authored 39 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 23 papers in Molecular Biology and 22 papers in Oncology. Recurrent topics in Youram Nassir's work include Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (11 papers). Youram Nassir is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (11 papers). Youram Nassir collaborates with scholars based in United States and Mexico. Youram Nassir's co-authors include James R. Berenson, Regina A. Swift, Ori Yellin, Robert Vescio, Ralph V. Boccia, James Hilger, Marshall S. Flam, Alberto Bessudo, Shahrooz Eshaghian and Dipti Patel‐Donnelly and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Youram Nassir

38 papers receiving 484 citations

Peers

Youram Nassir

HEMAT

ONCOL

GENET

PRM

Shyamala Navada United States

Neil Majithia United States

Osamu Iwase Japan

Leonard Minuk Canada

Jennifer K. Taylor United States

Brian Gibson United States

Zahida Yasin United States

Xiaoyue Wei China

Paulette Jacobs United States

Heleen Visser-Wisselaar Netherlands

Shyamala Navada United States

Youram Nassir

252 ×0.8

259 ×0.8

HEMAT

140 ×0.6

ONCOL

118 ×3.4

GENET

70 ×2.1

PRM

Citations per year, relative to Youram Nassir Youram Nassir (= 1×) peers Shyamala Navada

Countries citing papers authored by Youram Nassir

Since Specialization

Citations

This map shows the geographic impact of Youram Nassir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Youram Nassir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Youram Nassir more than expected).

Fields of papers citing papers by Youram Nassir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Youram Nassir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Youram Nassir. The network helps show where Youram Nassir may publish in the future.

Co-authorship network of co-authors of Youram Nassir

This figure shows the co-authorship network connecting the top 25 collaborators of Youram Nassir. A scholar is included among the top collaborators of Youram Nassir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Youram Nassir. Youram Nassir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, James, Tanya M. Spektor, Jacob D. Bitran, et al.. (2017). Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Supportive Care in Cancer. 25(10). 3217–3224. 2 indexed citations

Vardanyan, Suzie, James Wang, Nika M Harutyunyan, et al.. (2016). Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Annals of Hematology. 96(3). 449–459. 14 indexed citations

Vardanyan, Suzie, James Wang, Nika M Harutyunyan, et al.. (2016). Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. Annals of Hematology. 96(3). 441–448. 6 indexed citations

Berenson, James R., Laura Stampleman, Alberto Bessudo, et al.. (2015). Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 33(15_suppl). 8591–8591. 2 indexed citations

Berenson, James R., James Hilger, Ori Yellin, et al.. (2014). Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia. 28(7). 1529–1536. 55 indexed citations

Berenson, James R., Ori Yellin, Chien-Shing Chen, et al.. (2014). A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Supportive Care in Cancer. 23(6). 1503–1512. 27 indexed citations

Berenson, James R., James Hilger, Ori Yellin, et al.. (2013). A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Annals of Hematology. 93(1). 89–98. 34 indexed citations

Hilger, James, James R. Berenson, Leonard M. Klein, et al.. (2013). A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM).. Journal of Clinical Oncology. 31(15_suppl). 8598–8598. 3 indexed citations

Yellin, Ori, Chen‐Li Cheng, Alan Cartmell, et al.. (2012). A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia. 26(7). 1675–1680. 32 indexed citations

10.

Berenson, James R., Ori Yellin, Robert Dichmann, et al.. (2012). A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen.. Journal of Clinical Oncology. 30(15_suppl). 8098–8098. 5 indexed citations

11.

Berenson, James R., Ori Yellin, Alberto Bessudo, et al.. (2012). Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. British Journal of Haematology. 160(3). 321–330. 39 indexed citations

12.

Berenson, James R., Ori Yellin, Ravi Patel, et al.. (2011). A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. British Journal of Haematology. 155(5). 580–587. 25 indexed citations

13.

Berenson, James R., Ori Yellin, John Crowley, et al.. (2010). Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. American Journal of Hematology. 86(1). 25–30. 15 indexed citations

14.

Berenson, James R., Ori Yellin, Alan Cartmell, et al.. (2010). A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM). Blood. 116(21). 3044–3044. 2 indexed citations

15.

Berenson, James R., Ori Yellin, Donald Woytowitz, et al.. (2009). Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen. European Journal Of Haematology. 82(6). 433–439. 21 indexed citations

16.

Berenson, James R., Ori Yellin, Ravi Patel, et al.. (2009). A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research. 15(3). 1069–1075. 29 indexed citations

17.

Berenson, James R., Ori Yellin, Ravi Patel, et al.. (2009). A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).. Blood. 114(22). 4936–4936. 1 indexed citations

18.

Berenson, James R., Hank H. Yang, Robert Vescio, et al.. (2008). Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Annals of Hematology. 87(8). 623–631. 31 indexed citations

19.

Berenson, James R., Ori Yellin, Donald Woytowitz, et al.. (2007). Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.. Blood. 110(11). 3602–3602. 8 indexed citations

20.

Regunathan, Soundararajan, Youram Nassir, K. Sundaram, et al.. (1996). Expression of I2-imidazoline sites in rat prostate. Biochemical Pharmacology. 51(4). 455–459. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact